secwatch / observer

8-K filed June 1, 2026, 8:45 AM ET ticker TTRX CIK 0002023016

other material confidence high sentiment positive materiality 0.75

Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs

Turn Therapeutics Inc.

92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.
EASI-90 rates: 44.4% at Week 4 and 51.9% at Week 8 for GX-03 vs 30.4% and 34.8% vehicle.
No treatment-related serious adverse events, tolerability issues, or discontinuations reported.
Enrollment nearing completion; company optimizing trial endpoints and planning FDA meeting.
Detailed data to be presented at Jefferies Global Healthcare conference on June 4, 2026.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-063177
form_type: 8-K
ticker: TTRX
cik: 0002023016
company_name: Turn Therapeutics Inc.
filed_at: 2026-06-01T12:45:27+00:00
discovered_at: 2026-06-01T12:50:00.338664+00:00
generated_at: 2026-06-01T12:50:30.453868+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-063177
json_url: https://secwatch.observer/filing/0001213900-26-063177.json
markdown_url: https://secwatch.observer/filing/0001213900-26-063177.md
text_url: https://secwatch.observer/filing/0001213900-26-063177.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/0001213900-26-063177-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/ea0292880-8k_turn.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

LIXT

Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board

LIXTE BIOTECHNOLOGY HOLDINGS, INC. June 1, 2026, 8:55 AM ET other_material Items 5.02, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BMNR

Bitmine holds 5.42M ETH (4.49% of supply); total crypto + cash = $11.6B

BITMINE IMMERSION TECHNOLOGIES, INC. June 1, 2026, 8:45 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIRJ

AirJoule Technologies raises $15M in registered direct offering at $4.10/share

AirJoule Technologies Corp. June 1, 2026, 8:34 AM ET other_material Items 1.01, 5.07, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JSPR

Jasper Therapeutics initiates strategic review including potential sale or wind-down

Jasper Therapeutics, Inc. June 1, 2026, 8:01 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-26-063177

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.